Using post-bronchodilator FEV 1 is better than pre-bronchodilator FEV 1 in evaluation of COPD severity

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 3, 2012, Pages 276-280

  Chen, Chiung Zuei ^a   Ou, Chih Ying ^a   Wang, Wen Ling ^a   Lee, Cheng Hung ^a   Lin, Chien Chung ^a   Chang, Han Yu ^a   Hsiue, Tzuen Ren ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

Cchronic obstructive pulmonary disease; FEV1; GOLD criteria; Mmortality.; Ppost bronchodilator FEV1

Indexed keywords

BRONCHODILATING AGENT;

ADULT; AGED; AIRWAY OBSTRUCTION; ARTICLE; BODY MASS; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DISEASE SEVERITY; DYSPNEA; EVIDENCE BASED MEDICINE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MMRC DYSPNEA SCALE; MORTALITY; OUTCOME ASSESSMENT; PHENOTYPE; PRACTICE GUIDELINE; PREDICTIVE VALUE; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RATING SCALE; RESPIRATORY TRACT DISEASE; RISK FACTOR; SPIROMETRY; WHEEZING;

AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SPIROMETRY;

EID: 84862067689     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.654529     Document Type: Article

References (28)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2006 updated. Bethesda, MD: National Heart, Lung and Blood Institute/World Health Organization.
2. Anthonisen NR, Wright EC, Hodgkin JE. Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986; 133:14-20.
3. Ferrer M, Alonso J, Morera J, et al. Chronic obstructive pulmonary disease stage and health-related quality of life. Ann Intern Med 1997; 127:1072-1079.
4. Dewan NA, Rafi que S, Kanwar B, et al. Acute exacerbation of copd: Factors associated with poor treatment outcome. Chest 2000; 117:662-671.
5. Friedman M, Serby CW, Menjoge SS, Wilson JD, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in copd. Chest 1999; 115:635-641.
6. Burrows B. Predictors of loss of lung function and mortality in obstructive lung diseases. Eur Respir Rev 1991; 1:340-345.
7. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167:544-549.
8. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Healthrelated quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:680-685.
9. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350:1005-1012.
10. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: The updated BODE index and the ADO index. Lancet 2009; 374:704-711.
11. Briggs A, DPhil BA, Spencer M, et al. Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease. Arch Intern Med 2008; 68(1):71-79.
12. Blonshine S, Mottram CD, Wanger J. Pulmonary Function Laboratory Management and Procedure Manual, 2nd ed. American thoracic Society, New York, 2005.
13. Chen CZ, Lin CC, Lee CH, Chang HY, Hsiue TR. Small airways obstruction syndrome in clinical practice Respirology 2009; 14:393-398.
14. Calverly PM, Anderson JA, Celli BR, et al. Salmeterol and fl uticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356:775-789.
15. Tashkin DP, Celli BR, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008; 359:1543-1554.
16. Guell R, Casan P, Belda J, et al. Lomg-term eff ects of outpatient rehabilitation of copd. A randomized trial. Chest 2000; 117:976-983.
17. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-yaer survival than airway obstruction in patients with copd. Chest 2002; 121:1434-1440.
18. Schols AM, Soeters PB, Dingemans AM, et al. Prevalence and characteristics of nutritional depletion in patients with stable copd eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147: 1151-56.
19. Almagro P, Salvado M, Garcia-Vidal C, et al. recent improvement in long-term survival after a copd hospitalization. Th orax 2010; 65: 298-302.
20. Roberts CM, Lowe D, Bucknall CE, et al. Clinical audit indicators of outcome following admission to hospital with acute exacerbation of chronic obstructive pulmonary disease. Th orax 2002; 57:137-141.
21. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and motality in patients with chronic obstructive pulmonary disease. Th orax 2005; 60:925-931.
22. Sterk PJ. Let's not forget: The GOLD criteria for copd are based on post-bronchodilator FEV1. Eur Respir J 2004; 23:497-498.
23. Johannessen A, Omenaas ER, Bakke PS, et al. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: A community study. Th orax 2005; 60:842-847.
24. Ashley F, Kannel WB, Sorlie PD, et al. Pulmonary function: Relation to aging, cigarette habit, and mortality. Ann Intern Med 1975; 82:739-745.
25. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke OS, Murkve O. Risk of over diagnosis of copd in asymptomatic elderly never-smokers. Eur Respir J 2002; 20: 1117-1122.
26. Vestbo J, Lande P. Can GOLD stage 0 provide information or prognostic value in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166:329-332.
27. De Marco R, Accordini S, Cerveri I, et al. An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages. Th orax 2004; 59:120-125.
28. Kerstjens HA. The GOLD classifi cation has not advanced understanding of copd. Am J Respir Crit Care Med 2004; 170:212-213.